Halozyme granted European patent covering ENHANZE drug delivery platform

Halozyme Therapeutics announced the grant of European Patent No. 4269578, covering the ENHANZE rHuPH20 product obtained from Halozyme’s ENHANZE manufacturing methods that the company provides to its current and future licensees. The new patent is licensed under all of Halozyme’s ENHANZE licenses. It will be validated in 37 European countries and expires on March 6, 2029.